257 related articles for article (PubMed ID: 22262746)
1. Everolimus alters white matter diffusion in tuberous sclerosis complex.
Tillema JM; Leach JL; Krueger DA; Franz DN
Neurology; 2012 Feb; 78(8):526-31. PubMed ID: 22262746
[TBL] [Abstract][Full Text] [Related]
2. Diffusion tensor imaging identifies changes in normal-appearing white matter within the epileptogenic zone in tuberous sclerosis complex.
Widjaja E; Simao G; Mahmoodabadi SZ; Ochi A; Snead OC; Rutka J; Otsubo H
Epilepsy Res; 2010 May; 89(2-3):246-53. PubMed ID: 20129760
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex.
Peters JM; Prohl A; Kapur K; Nath A; Scherrer B; Clancy S; Prabhu SP; Sahin M; Franz DN; Warfield SK; Krueger DA
Pediatr Neurol; 2019 Jan; 90():24-30. PubMed ID: 30424962
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
5. New therapies for tuber-less sclerosis: white matter matters?
Ess KC; Roach ES
Neurology; 2012 Feb; 78(8):520-1. PubMed ID: 22262747
[No Abstract] [Full Text] [Related]
6. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
9. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
Krueger DA; Wilfong AA; Holland-Bouley K; Anderson AE; Agricola K; Tudor C; Mays M; Lopez CM; Kim MO; Franz DN
Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal changes in diffusion properties in white matter pathways of children with tuberous sclerosis complex.
Baumer FM; Song JW; Mitchell PD; Pienaar R; Sahin M; Grant PE; Takahashi E
Pediatr Neurol; 2015 Jun; 52(6):615-23. PubMed ID: 25817702
[TBL] [Abstract][Full Text] [Related]
11. Cerebral diffusion tensor imaging in tuberous sclerosis.
Piao C; Yu A; Li K; Wang Y; Qin W; Xue S
Eur J Radiol; 2009 Aug; 71(2):249-52. PubMed ID: 18538521
[TBL] [Abstract][Full Text] [Related]
12. Diffusion tensor imaging of normal white matter maturation from late childhood to young adulthood: voxel-wise evaluation of mean diffusivity, fractional anisotropy, radial and axial diffusivities, and correlation with reading development.
Qiu D; Tan LH; Zhou K; Khong PL
Neuroimage; 2008 Jun; 41(2):223-32. PubMed ID: 18395471
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis complex.
Makki MI; Chugani DC; Janisse J; Chugani HT
AJNR Am J Neuroradiol; 2007 Oct; 28(9):1662-7. PubMed ID: 17893226
[TBL] [Abstract][Full Text] [Related]
14. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in the human corpus callosum microstructure: a combined T2 myelin-water and diffusion tensor magnetic resonance imaging study.
Liu F; Vidarsson L; Winter JD; Tran H; Kassner A
Brain Res; 2010 Jul; 1343():37-45. PubMed ID: 20435024
[TBL] [Abstract][Full Text] [Related]
16. Similar white matter aberrations in children with autism and their unaffected siblings: a diffusion tensor imaging study using tract-based spatial statistics.
Barnea-Goraly N; Lotspeich LJ; Reiss AL
Arch Gen Psychiatry; 2010 Oct; 67(10):1052-60. PubMed ID: 20921121
[TBL] [Abstract][Full Text] [Related]
17. When, where, and how the corpus callosum changes in MCI and AD: a multimodal MRI study.
Di Paola M; Di Iulio F; Cherubini A; Blundo C; Casini AR; Sancesario G; Passafiume D; Caltagirone C; Spalletta G
Neurology; 2010 Apr; 74(14):1136-42. PubMed ID: 20368633
[TBL] [Abstract][Full Text] [Related]
18. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
[TBL] [Abstract][Full Text] [Related]
19. Voxel-based analysis of white matter during adolescence and young adulthood.
Qiu M; Li Q; Liu G; Xie B; Wang J
Brain Dev; 2010 Aug; 32(7):531-7. PubMed ID: 19740616
[TBL] [Abstract][Full Text] [Related]
20. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
